Agoracom Blog Home

Posts Tagged ‘CSE’

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:19 AM on Saturday, September 25th, 2021

A weekly summary of Novamind news and media, including the announcement of our inclusion in the NYSE Listed AdvisorShares Psychedelics ETF and more.

September 21, 2021

Burnout and the wounded healer​

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Paul Thielking. Paul is a psychiatrist, zen practitioner, and Chief Scientific Officer at Novamind. They discuss healthcare provider burnout and other unique challenges of being in the helping/healing professions.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

View all media

Novamind Announces Inclusion in NYSE Listed AdvisorShares Psychedelics ETF​

We are pleased to announce that we have been included in the AdvisorShares Psychedelics ETF trading on the NYSE under the ticker “PSIL” (the “ETF”).

PSIL is the first U.S.-listed, actively managed exchange traded fund to deliver dedicated investment exposure to psychedelics. PSIL seeks long-term capital appreciation by investing in the rapidly evolving psychedelics space, offering exposure to companies which the ETF’s portfolio manager views as leading the way in this nascent industry. The ETF currently includes 22 psychedelics companies. 

“The inclusion of Novamind in the AdvisorShares Psychedelics ETF is an important achievement for our Company,” commented Yaron Conforti, CEO and Director of Novamind. “Our clinics and clinical research sites are growing rapidly, and we are pleased to be recognized as a leading company in the emerging psychedelics sector.” 

Additional information on the ETF can be found here.

September 20, 2021

Novamind to Present at Benzinga Healthcare Conference​

Novamind to be featured in panel discussion on the disruptive potential of psychedelic medicine in mental healthcare

We will participate in the Benzinga Healthcare Small Cap Conference taking place virtually on September 29-30, 2021.

Novamind’s CEO and Director, Yaron Conforti, will join a panel of industry leaders for a discussion titled, “Addressing Mental Health through Emerging Therapies” on Thursday, September 30 at 12:35 PM EST.

Following the panel, from 1:15 PM to 1:30 PM EST, Mr. Conforti will deliver a presentation to update investors on the Company’s rapidly growing network of psychiatry clinics and clinical research sites focused on psychedelic medicine. A short Q&A session will follow.

For more information about the event and to register for free, visit: www.benzinga.com/events/small-cap/healthcare/

September 23, 2021

Novamind Announces DTC Eligibility for its Common Shares​

We are pleased to announce that our common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the U.S.

The DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered ‘DTC eligible’. This electronic method of clearing securities speeds up the receipt of stock and cash and accelerates the settlement process for investors and brokers. 

“We are pleased to have become DTC eligible. Investors will benefit from the accelerated settlement process and ability to trade Novamind shares through a wide range of U.S. brokerage firms,” said Yaron Conforti, Chief Executive Officer and Director of Novamind. “This is an important step towards increased liquidity for our stock and building a strong presence for Novamind in the U.S. capital markets.”

September 24, 2021

View all press releases

Mental Health, With a Side of Psychedelics?

A recap of some of the most promising psychedelic drugs for mental health and some of the trailblazers paving the way for the psychedelic revolution. “Sleep, exercise, therapy and antidepressants are some of the top remedies prescribed to assist the 1 in 4 Americans who struggle with mental health issues. But while these are all critical and effective tools, are they enough?”

Psychedelics Are a Billion-Dollar Business, and No One Can Agree Who Should Control It

Novamind’s business model was structured to be drug agnostic. We want to be able to provide the best possible therapies for our clients, regardless of what therapies they end up needing. It’s why we’re a champion for increasing access to all psychedelics. In this article, Shayla Love covers how those interested in psychedelics are learning to work together for the greater good. 

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

VIDEO – Valeo Pharma (VPH:CSE) Reported Record Q3-21 Revenue of $5.7 million, up 280% over Q3-20

Posted by AGORACOM-JC at 5:22 PM on Thursday, September 23rd, 2021
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. 

The company recently released Q3 results and highlights:

·  Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.

·  Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.

·  Record 9 months revenues at $10.2 million , up 94%.

·  Private and public reimbursement coverage expanding for Redesca®

·  New corporate structure completed with full commercial activities ongoing for Redesca®, Enerzair® Breezhaler® and Atectura® Breezhaler®

As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.

Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.

VIDEO – Draganfly Selected As Exclusive Drone Manufacturer To Address “Last Inch” Package Logistics, Initial Order $400K

Posted by AGORACOM-JC at 4:36 PM on Wednesday, September 22nd, 2021

Most of us know drones for their recreational uses or perhaps even as simple commercial applications for things like real estate videos.  

But the fact of the matter is that drone usage is about to go parabolic with huge corporations adopting them for a wide-use of applications that most never dreamed of such as: 

  • To provide Internet connections in remote locations. 
  • To collect crowd data.
  • And now package delivery

According to the Drone Package Delivery Global Market Report 2021, the global drone package delivery market is expected to grow to nearly US$1 billion in 2021 at a compound annual growth rate (“CAGR”) of 45.5%. In 2025, the market is expected to reach US$4.4 billion at a CAGR of 45.1%.

In short, the drone industry is booming in ways people can’t imagine because the industry is shifting from the drones themselves (hardware) to drone technology and solutions (software)… and the one company that is delivering the most challenging applications is Draganfly Inc. (DPRO: NASDAQ) (DPRO: CSE)

DraganFly is an award-winning drone manufacturer and technology developer that is actually delivering some pretty incredible achievements, milestones and even history:

  • Established in 1998 DFLY is considered the oldest commercial drone company in the world
  • Built the first drone that saved a life
  • Boasts the first drone to be inducted into the Smithsonian National Air & Space Museum
  • Developing a Vaccine Drone Delivery Payload System (it’s way more complicated than just transporting vaccines)
  • Detect infectious conditions in a person from a distance of 190 feet
  • Conduct phenotyping, data collection and analysis by the USDA

·       Vital Intelligence Smart Vital System Now Available in Fobi’s Venue Management System for Conferences & Events

Clients include:

  • NASCAR
  • Ford
  • Warner Brothers
  • Suncor Energy
  • Shell
  • Redbull
  • Government of Canada 
  • Ontario Provincial Police, 
  • Australian Federal Police, 
  • Royal Canadian Mounted Police, 
  • Illinois State Police,
  • Shell
  • Dow 

If you want ultra-cool consider that DFLY’s Vital Intelligence technology was selected for implementation by Knightscope, a leader in a leader in autonomous robot security capabilities.  

All of this has translated into financial success with 2020 Revenue hitting $4.36M up 216% … and Q2-21 revenue of just under $2M up 114% vs Q2-20.

With all of this under the Company’s belt, it’s easy to see why the company recently uplisted to the NASDAQ.

If you believe in the massive parabolic growth in the use of drones for almost everything we do in this world, or want to learn, then watch / listen to this powerful interview with Draganfly CEO and Chairman, Cameron Chell.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:22 AM on Saturday, September 18th, 2021

A weekly summary of Novamind news and media, including the announcement of our selection as a research site for Karuna Therapeutics.

September 14, 2021

What Is Psycholytic Ketamine Assisted Psychotherapy?

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by returning guest, Vhari Macbeth to discuss psycholytic ketamine-assisted psychotherapy (KAP).

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

View all media

Novamind to Serve as Research Site for Karuna Therapeutics Late-Stage Clinical Trial

We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a clinical trial sponsored by Karuna Therapeutics, Inc., a clinical-stage neuroscience biopharmaceutical company

The phase III study will evaluate the investigational therapy KarXT for the treatment of schizophrenia, a serious and potentially disabling condition affecting approximately 20 million people worldwide.

Dr. Reid Robison, Novamind’s Chief Medical Officer and Principal Investigator at CCR said, “We need more innovation in this field and I’m hopeful to see compounds like KarXT that have new ways of acting on the brain and the potential for improved efficacy and side effect profiles.”

September 13, 2021

View all press releases

Legalising Illicit Therapies: Why Psychedelics Could Be The Most Important Mental Health Breakthrough Of The 21st Century

As psychedelics continue to break free from the stigma surrounding them, more and more people are seeing the promise these drugs have in changing the way we treat mental health. “Recent trials are showing that psychedelics are proving not only successful but also incredibly effective when stacked up against traditional forms of treatment, with one recent trial reporting that they are up to four times more effective than antidepressants.”

The DEA Seeks To Increase Federal Production Limits For Psilocybin And Marijuana Research

In a big step forward for psychedelic research, the DEA is set to increase limits for psilocybin. From the DEA: “DEA firmly believes in supporting regulated research of schedule I controlled substances.” We look forward to increased research and have a dedicated psychedelic contract research organization (CRO) in Cedar Clinical Research, capable of studying promising new treatments.

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

Was this email forwarded to you?
Subscribe to our weekly newsletter

VIDEO – Liquid Avatar $LQID Part Of Consultations Around Ontario Plan For Digital ID By End Of 2021

Posted by AGORACOM-JC at 5:40 PM on Monday, September 13th, 2021

12 months ago investors couldn’t be blamed if they found it hard to grasp the genius and foresight of Liquid Avatar $LQID $LQAVF ….. the easiest way to describe the company was as a blockchain platform allowing people to manage & profit from their digital identity, which became a real need once global laws started being enacted to prevent the likes of Facebook from every abusing our private information again.

It sounded great … and definitely sounded like something valuable 3-4 years into the future … but then the signs started showing up that painted an accelerating picture that would put LQID at the forefront of digital identity.

1.  In March of this year, Google validated the $LQID business model with this stunning announcement:

 Google announces major shift away from precision-targeting of ads based on everything you do on the interne

  • Google believes these types of tracking methods don’t “meet rising consumer expectations for privacy, nor will they stand up to rapidly evolving regulatory restrictions, and therefore aren’t a sustainable long term investment.
  • Google is experimenting with tools in its Privacy Sandbox that are designed to allow advertising to continue to work on the web but in a less privacy-encroaching way.
  • “Keeping the internet open and accessible for everyone requires all of us to do more to protect privacy — and that means an end to not only third-party cookies, but also any technology used for tracking individual people as they browse the web,” David Temkin, Google’s director of product management for ads privacy and trust,

 What is the potential outcome of this major shift by Google?

  “Google’s decision could upend the ad industry, which has relied on these types of tracking tools”  

Now the data privacy and monetization game is underway with LQID sitting in a great position within the industry and the dominant position within the small cap world.  

2.  In May of this year, The Ontario government released its digital identity strategy outlining ways in which it plans to harness the potential of the digital economy and better utilize data. Included in the plan are tangible commitments.

Then came the news all Liquid Avatar investors were waiting for: 

Ontario Releases Technology and Standards for Digital Identity which includes: 

  • the creation of a new data authority;
  • the introduction of a new government-issued digital ID that lets people prove who they are both online and in person

ENTER LIQUID AVATAR

Enter $LQID whose Liquid Avatar Verifiable Credentials Ecosystem (LAVCE) is being built to support all participants in a digital credential ecosystem, including the Holder, Issuer and Verifier, using state-of-the-art blockchain and open standards technologies – initially as a node on the Indicio Network.  More than just a good idea, $LQID issued a press release announcing the following:

“Ontario is one of the first jurisdictions in North America to announce that it will issue and enable digital credentials – and it has been a great experience working with the government on this both directly and through our role in membership organizations like the Trust Over IP Foundation”

AND

“Liquid Avatar Technologies has been a part of the ongoing consultations around the province’s plan to introduce a digital identification credential by the end of 2021”

Make no mistake about it.  This is a simply massive paradigm shift and $LQID isn’t going to tackle this on its own.  The Company is a voting and steering committee member of the Trust over IP Foundation, founding and steering committee member of Cardea, a Linux Foundation Public Health project, member of the Good Health Pass collaborative, ID2020, DIACC, The Linux Foundation and a founding member of the Lumedic Exchange.

Suddenly it is getting easy to see the genius of Liquid Avatar.

Watch this great interview with CEO David Lucatch.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:54 AM on Saturday, September 11th, 2021

A weekly summary of Novamind news and media, including the announcement of our uplisting to the OTCQB Market and much more.

September 7, 2021

Treating Trauma with Psychedelic-Assisted Psychotherapy

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Hannah Cross to discuss how psychedelic-assisted psychotherapy is used to treat trauma.

August 31, 2021

Treating Eating Disorders with Ketamine-Assisted Psychotherapy

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss how ketamine-assisted psychotherapy is used to treat eating disorders

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

View all media

Novamind Uplists to OTCQB Venture Market

We pleased to announce our common shares have been approved for trading under the ticker symbol “NVMDF” on the OTCQB® Venture Market, a U.S. trading platform operated by the OTC Markets Group, Inc.

“With this listing, we look forward to expanding Novamind’s presence in the U.S. and deepening our relationships with a broad base of institutional and retail investors.” said Yaron Conforti, CEO and Director.

September 9, 2021

Novamind to Present at H.C. Wainwright 23rd Annual Global Investment Conference

CEO and Director, Yaron Conforti, will present the Company’s business model focused on growing a national network of psychiatry clinics and clinical research sites to rapidly scale access to psychedelic medicine.

Learn more about the Conference and register to schedule a one-on-one meeting with Novamind’s management here.

September 8, 2021

View all press releases

The Worldview-Changing Drugs Poised to Go Mainstream

BBC Future covers the experience, culture and future of psychedelics and “what might follow if psychedelics become mainstream.” It’s a popular theme in this week’s roundup: what the world will look like after the psychedelic revolution. “Psychedelics offer something that few other things can: an experience well beyond what our everyday reality could conceive or expect.” With such life changing drugs and therapies becoming available, there’s no doubt the future will look a lot different.

Neurocognitive Effects of Ketamine for Depression Examined

This article delivers more positive news about ketamine and esketamine, which we currently use in our Cedar Psychiatry clinics. Learn more about how we use these powerful drugs here. “Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression, according to a review published online Aug. 5 in the Harvard Review of Psychiatry.”

Psychedelic Treatments Are Here, But Doctors Aren’t Prepared

Rick Doblin and Jennifer Ouyang Altman lay out the potential risks of not having standardized psychedelic education for providers. It’s a problem that will arise as psychedelics continue to move into the mainstream. It’s one reason why education is such a big component of our mission to increase access to psychedelic medicine. On the Psychedelic Therapy Frontiers podcast, we cover topics across the spectrum from trip-sitting to treating trauma with psychedelic-assisted psychotherapy. Another way we’re helping address this issue is by creating psychedelic treatment protocols, sharing best-in-class techniques and procedures with the wider population. Learn more here.

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

Was this email forwarded to you?
Subscribe to our weekly newsletter

VIDEO – Liquid Avatar $LQID Blockchain Powered Digital ID and Health Credentials Is The Genius App Most Couldn’t See 12 Months Ago

Posted by AGORACOM-JC at 4:25 PM on Thursday, September 2nd, 2021

12 months ago investors couldn’t be blamed if they found it hard to grasp the genius and foresight of Liquid Avatar $LQID $LQAVF ….. the easiest way to describe the company was as a blockchain platform allowing people to manage & profit from their digital identity, which became a real need once global laws started being enacted to prevent the likes of Facebook from every abusing our private information again. 

It sounded great … and definitely sounded like something valuable 3-4 years into the future … but then the signs started showing up that painted an accelerating picture that would put LQID at the forefront of digital identity.

1.  Google validated the $LQID business model with this stunning announcement at the beginning of March:

 Google announces major shift away from precision-targeting of ads based on everything you do on the internet

  • Google believes these types of tracking methods don’t “meet rising consumer expectations for privacy, nor will they stand up to rapidly evolving regulatory restrictions, and therefore aren’t a sustainable long term investment.”
  • Google is experimenting with tools in its Privacy Sandbox that are designed to allow advertising to continue to work on the web but in a less privacy-encroaching way.
  • “Keeping the internet open and accessible for everyone requires all of us to do more to protect privacy — and that means an end to not only third-party cookies, but also any technology used for tracking individual people as they browse the web,” David Temkin, Google’s director of product management for ads privacy and trust,

 What is the potential outcome of this major shift by Google?

  “Google’s decision could upend the ad industry, which has relied on these types of tracking tools”  

Now the data privacy and monetization game is underway with LQID sitting in a great position within the industry and the dominant position within the small cap world.  

2.  The Ontario government released its digital identity strategy outlining ways in which it plans to harness the potential of the digital economy and better utilize data. Included in the plan are tangible commitments such as: 

  • the creation of a new data authority; 
  • the introduction of a new government-issued digital ID that lets people prove who they are online.

THEN CAME COVID-19 TEST AND VACCINATION CREDENTIALS 

Both of these happened BEFORE governments around the world started announcing “Vaccine Passports” that would require people to prove their vaccinations prior to accessing some of the biggest parts of society.  But with the Quebec system already getting hacked before it started, the government initiatives are easier said than done.

Enter $LQID whose Liquid Avatar Verifiable Credentials Ecosystem (LAVCE) is being built to support all participants in a digital credential ecosystem, including the Holder, Issuer and Verifier, using state-of-the-art blockchain and open standards technologies – initially as a node on the Indicio Network.  

The Company is also a voting and steering committee member of the Trust over IP Foundation, founding and steering committee member of Cardea, a Linux Foundation Public Health project, member of the Good Health Pass collaborative, ID2020, DIACC, The Linux Foundation and a founding member of the Lumedic Exchange.

12 months later and it is now getting easy to see the genius of Liquid Avatar.

Watch this great interview with CEO David Lucatch.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:59 AM on Saturday, August 28th, 2021

A weekly summary of Novamind news and media

August 24, 2021

Pairing Ketamine with EMDR & Other Therapy Methods

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Bob Mcnutt to discuss how ketamine is combined with a variety of psychotherapy modalities, particularly Eye Movement Desensitization and Reprocessing (EMDR).

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

View all media

Peace Blockade

Erinn Baldeschwiler is just “looking for a sense of peace as she dies.” Baldeschwiler has terminal breast cancer and has tried to turn to psilocybin therapy, under the Right to Try Act, to help. But it hasn’t been that simple. It’s why she and other patients in similar situations are taking it to the courtroom. The case is set for next month, with the potential for a decision to come as early as this fall. “For Baldeschwiler, a safe and caring treatment plan involving psilocybin may be what helps her find peace. For her, now is the time to act — she doesn’t have much of it to spare.”

New UW Center to Study Emerging Field of Psychedelic Compounds for Medical Treatments

Exciting news out of Wisconsin as the Transdisciplinary Center for Research in Psychoactive Substances is announced. “Four clinical trials in phases 1 to 3 are currently underway at UW–Madison to prepare for submitting applications for new drugs to the Food and Drug Administration.” The center has stated it will seek to include more minorities and marginalized groups in their research.

Researchers Work to Integrate Psychedelic Drug and Music Therapies Using Technology

Music and psychedelics have a long history together. And now, some tech companies “are designing music to help you get the most out of your trip,” creating music to enhance the therapeutic potential of psychedelics.

Follow @novamind_inc on Instagram

VIDEO – Biomind Labs (BMND : NEO) Is Developing The Next Generation of Medicines For The 21st Century – The Pharmaceutical Side of Psychedelics

Posted by AGORACOM-JC at 4:40 PM on Wednesday, August 25th, 2021
Biomind Labs Inc. Completes Reverse Take-Over Transaction | Business Wire

Alejandro Antalich, CEO of Biomind. “We, both, are driven by innovation. At Biomind, our objective is to change the course of medicine by assisting doctors in potentially saving more lives and providing a better quality of life to millions of people suffering from addiction, chronic pain, depression, anxiety, and other mental health disorders.

Biomind Labs is Developing the next generation of medicines for the 21st century … the pharmaceutical side of psychedelics

THE PROBLEM

● Depression and anxiety cost the global economy US$ 1 trillion each year

  • ~ 20% of the world’s children and adolescents have a mental health condition
  • Suicide is the second leading cause of death among 15-29 year-olds
  • 13% rise in mental health conditions & substance use disorders in last decade (to 2017)
  • Mental health conditions now cause 1 in 5 years lived with disability

#Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety and depression amongst other things

More than 80% of the global population prefers natural products as sources of new drug candidates …

and that is good because Biomind’s vertical integration approach – Transforming natural psychotropic compounds into pharmaceuticals  – creating drug therapies that harness the medicinal power of natural psychedelic compounds

1 indication is already in Phase 2 … 3 indications in Phase 2 by end 2021 … 3 in Phase 3 by end 2022.

Sit back, relax and watch this powerful interview with Alejandro Antalich, Chief Executive Officer of Biomind Labs.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:34 AM on Saturday, August 21st, 2021

A weekly summary of Novamind news and media

August 17, 2021

Psychedelics, Psychosis, & the Abuse Potential of Ketamine

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison talk about the relationship between psychedelics and psychosis and discuss the abuse potential of ketamine.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com 

View all media

Psychedelics are getting closer to approval, but the market may not be ready

Amirah Al Idrus explores the regulatory issues facing psychedelics, the setting in which they’re administered and how traditional business models may need to evolve in the process. At Novamind, we’re building the infrastructure to expand access to psychedelics in anticipation of their FDA approval. We’ve developed and are developing psychedelic therapy protocols to target difficult-to-treat mental health conditions that are underserved by the current standard of care. You can learn more about those treatment protocols here.

We Just Got Closer to Understanding Why Ketamine Is Such a Powerful Antidepressant

We know ketamine’s power to treat depression. “Within hours, a single dose of the psychedelic substance has been shown to curb suicidal intent, and recent clinical trials suggest these effects work on two thirds of patients, lasting for up to several weeks before fading away.” But recent results are getting us closer to the scientific reason why—ketamine may be responsible for decreasing the release of glutamate in our brains. 

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

Subscribe to our weekly newsletter